BigBear.ai Hldgs 株価情報 (NYSE: BBAI)

最新ニュース BigBear.ai Hldgs (NYSE:BBAI) 株価情報

BIGBEAR.AI HOLDINGS INC

BigBear.ai Hldgs

BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment. Company generate revenue by providing customers with Edge AI-powered decision intelligence solutions and services for data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics and predictive visualization. It generate revenue from providing both software and services to customers.

BigBear.ai Holdings Inc

BigBear.ai, Inc. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share

StoneX Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNEX#NASDAQ">SNEX</a>), a global financial services firm, today announced it has entered into a letter of intent to acquire Intercam Advisors, Inc. and Intercam Securities, Inc. from Intercam Holdings, Inc.
The proposed acquisition remains subject to the negotiation and execution of definitive agreements, which will be subject to regulatory approvals and other closing conditions.
"This transaction aligns with StoneX's strategy of expanding its global wealth management footprint, particularly in Latin America, and providing clients with broader access to markets and investment products," said Jay Carter, CEO of StoneX Wealth Management.
The parties are working toward finalizing terms and entering into a definitive agreement in the near future.

SNEX

StoneX Group Signs Letter Of Intent To Acquire Intercam Advisors To Expand Latin America Wealth Management; Financial Terms Not Disclosed

Goldman Sachs analyst Anthony Valentini initiates coverage on AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) with a Buy rating and announces Price Target of $301.

News

Price Target

Initiation

Analyst Ratings

AVAV

Goldman Sachs Initiates Coverage On AeroVironment with Buy Rating, Announces Price Target of $301

VUZI

Vuzix Added To Russell 3000 And Russell 2000 Indexes

Guggenheim analyst Michael Morris maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and raises the price target from $120 to $140.

Guggenheim Maintains Buy on Walt Disney, Raises Price Target to $140

YXT.com Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) ("YXT.com" or the "Company"), a provider of&nbsp;AI-enabled&nbsp;enterprise productivity solutions, today announced that Mr. Pun Leung Liu has notified the board of directors of the Company (the "Board") of his decision to&nbsp;resign&nbsp;from his position as a Director and Chief Financial Officer ("CFO") of the Company, effective June 30, 2025, due to personal reasons.
Mr. Liu's resignation did not result from any disagreement or dispute with the Company, the Board, or the Company's management regarding any matter relating to the Company's operations, policies, or practices.
Following Mr. Liu's resignation, the Board has appointed Mr. Yazhou Wu, the Company's Chief Operating Officer and Chief Technology Officer, as the new Director. The Board has also appointed Mr. Shen Cao, the current Vice President of Investment Relations, as the new CFO.
Mr. Shen Cao joined the Company in May 2025 as Vice President of Investment Relations. Prior to joining YXT.com, Mr. Cao served as the Deputy Chairman of the Board in Topsperity Securities Asset Management Co., Ltd. from June 2023 to April 2025. Mr. Cao holds a Bachelor's and Master's degree in Civil Engineering from Tsinghua University.

Management

YXT.com CFO Pun Leung Liu Resigns; Shen Cao Appointed As Successor, Effective June 30, 2025

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30090136/Honor-0630-900x600-1.png" alt="" class="wp-image-15071" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30090136/Honor-0630-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30090136/Honor-0630-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/30090136/Honor-0630-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The former Huawei unit that became an independent smartphone brand in 2020 has taken an important step towards an IPO on China's A-share market that could come next year
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The Honor smartphone brand is advancing toward a 2026 IPO while repositioning itself as an AI company to attract investors</li>
<li>Despite losing market share to rivals in China, the former Huawei unit is showing strong overseas growth in Europe and Asia</li>
</ul>
Smartphone makers are increasingly looking to artificial intelligence (AI) to jumpstart growth by bringing new interactive functions to their increasingly mature products. Accordingly, many are trying to rebrand themselves as AI companies rather than traditional hardware manufacturers, a strategic shift that could help them generate new buzz and functionality around their models.
Such a narrative is a central strategy for China's&nbsp;Honor Device Co. Ltd., which has spent much of this year positioning itself as evolving into a "globally leading AI device ecosystem company." Such messaging has taken on added urgency as Honor chases a public listing, in which it hopes to showcase its AI credentials as a central attraction for potential investors.
The company's IPO plans advanced significantly last week when it received&nbsp;<a href="https://m.caixin.com/m/2025-06-27/102335423.html?utm_source=Subscription+Pool&amp;utm_campaign=140fb6ec48-EMAIL_CAMPAIGN_5_13_2020_3_37_COPY_01&amp;utm_medium=email&amp;utm_term=0_4f3ff79ef1-140fb6ec48-72183648&amp;cx_referer=https%3A%2F%2Fwww.caixin.com%2F2025-06-27%2F102335423.html">regulatory approval</a>&nbsp;to enter the "tutoring process" for a listing on China's A-share markets in Shanghai and Shenzhen, which are mostly available to domestic investors. That tutoring process involves a comprehensive review for any prospective company wishing to list, during which its operations and financials undergo regulatory scrutiny. Companies can file a formal IPO prospectus only after completing the process.
An IPO would mark a successful end to a lengthy journey for Honor, whose listing has been the source of speculation since at least 2021 when reports suggested the company was considering a backdoor listing using a shell company. Similar rumors have surfaced repeatedly since then, gaining momentum late last year when Honor&nbsp;<a href="https://thebambooworks.com/its-shareholding-reform-rolled-up-honor-is-ready-for-ipo/">restructured as a joint-stock limited company</a>, typically a prerequisite for going public.
A listing path for Honor, a former unit of embattled&nbsp;Huawei Technologies&nbsp;that is now an independent company, still has considerable ground to cover. According to the China Securities Regulatory Commission, the company is scheduled to complete its listing tutoring between January and March next year, with leading domestic brokerage Citic Securities acting as its tutoring broker. This timeline suggests Honor's IPO could occur as early as the second quarter of 2026.
<h4 class="wp-block-heading">Struggles at home</h4>
Honor was established in 2013 as a value-oriented sub-brand for Huawei, whose own brand was focused on the premium end of the market, in hopes of someday taking on Apple's iPhone. When major U.S. sanctions in late 2020 threatened Huawei's ability to obtain smartphone chips and other U.S. technology, the parent spun off Honor to give the brand a better chance of survival by allowing it to maintain access to its American suppliers.
The consortium that purchased Honor was a hodgepodge of state-run entities and private investors, mostly from Huawei's hometown in the southern boomtown of Shenzhen.
This strategy allowed Honor to avoid the same fate as Huawei's smartphone business. Honor flourished in the years following the spinoff, partly by filling the market void left by Huawei as it retreated from the global market and was also forced to retreat at home. U.S. sanctions nearly crippled Huawei's smartphone operations, and the company has only recently recovered after finding substitutes for components and other products it previously sourced from the U.S.
Honor's post-spinoff performance was initially impressive. In 2022, it was the only smartphone brand among China's top five to record shipment growth, posting a 34% increase and capturing 12% of the Chinese market to become the country's second-largest brand, according to industry research firm IDC. The momentum continued into early 2024, when Honor claimed the top position with 17.1% of the Chinese market in the first quarter after achieving 13.2% sales growth.
However, Honor's trajectory has since reversed. Its Chinese market share declined steadily through 2024, dropping from 14.5% in the second quarter to 13.7% in the fourth. By the first quarter of 2025, Honor had fallen out of the top five vendors in China, according to IDC. Counterpoint Research shows it ranked sixth for the period, with shipments down 12.8%.
Honor's market struggles have coincided with strong growth from domestic rivals, particularly its former parent, as Huawei mounted its comeback. Huawei returned to the market in late 2023 with its Mate 60 series featuring domestically produced chipsets. During the first quarter of 2025, while Honor's sales were falling, Huawei's shipments surged 28.5% and&nbsp;Xiaomi's&nbsp;(1810.HK) rose 16.5%, according to Counterpoint.
Despite domestic challenges, Honor has performed strongly overseas – a marketplace where Huawei hasn't ventured due to its lack of access to Google's Android system that is one of the two main smartphone operating systems used worldwide. The company achieved impressive growth in Europe in last year's fourth quarter, with its shipments rising 77% year-over-year to become the market's fourth biggest brand with 4% share.
International expansion represents a significant bright spot for Honor and could serve as an important draw for investors. Honor is also steadily gaining ground in Southeast Asia. While it has not yet broken into the region's top five vendors, its growth trajectory has been remarkable, including 88% year-over-year growth in the first quarter of 2025 to a record 893,000 units shipped in the region, according to Canalys.
The temporary loss of market share in Honor's home market is not necessarily cause for alarm, and the company could well recover with compelling new product launches. However, the Chinese smartphone market remains intensely competitive, and China represents Honor's most critical market — one it cannot afford to cede to rivals.
To stand out from the crowd, Honor is trying to position itself as an AI-driven company. The company tried to highlight that strategy at the Mobile World Congress in Barcelona in March, announcing plans to invest $10 billion in AI over the next five years as part of its transformation from a smartphone manufacturer into an "AI device ecosystem company."
The repositioning has involved substantial organizational changes. Among those, Honor has established a new AI industrial division and expanded its AI and software teams to 2,600 employees, according to local media reports.
Honor's new CEO Li Jian, who took the helm in January, has told local media that smartphones represent a mature market where achieving the historical growth rates of 10% to 20% is no longer feasible. In contrast, he described AI phones as a "blue ocean market" where Honor's years of accumulated expertise in AI algorithms and hardware development give it competitive advantages.
That said, AI is hardly Honor's exclusive domain, but rather an industry-wide trend, with competitors like Xiaomi and Vivo pursuing similar strategies. Many analysts question whether the current crop of AI capabilities, which are limited, are compelling enough for consumers to consider upgrading their devices.
At the end of the day, repositioning itself as an AI company may enhance Honor's profile, though investor interest will more likely hinge on the fundamentals of its smartphone business. While things don't look great for the company in China, Honor's expanding presence in overseas markets, particularly in Europe and Southeast Asia, could still prove attractive to potential investors.

Former Huawei Business Honor Setting Up For 2026 IPO

WIIM

ABAT

American Battery Technology shares are trading higher amid its addition to the Russell 2000 and 3000 indexes, which will occur today.

LGHL

Lion Group shares are trading higher after the company announced it acquired $5 million worth of HYPE, Solana, and Sui as part of its multi-chain treasury strategy.

Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company's lead investigational compound, MNV-201. The FDA has also granted Rare Pediatric Disease Designation to MNV-201, which is in Phase 2 clinical trials for the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting children.
The Company also recently announced entry into a definitive business combination agreement (the "Business Combination Agreement") with Launch One Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPAA#NASDAQ">LPAA</a>, "Launch One"))), a publicly traded special purpose acquisition company. Following the expected closing of the transaction contemplated by this Business Combination Agreement (the "Business Combination"), projected for late 2025, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.

Biotech

General

LPAA

Minovia Therapeutics' MNV-201 Receives FDA Fast Track And Rare Pediatric Disease Designations For Pearson Syndrome Treatment

Orangekloud Technology Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) ("Orangekloud" or "the Company"), a Singapore-based technology company offering the eMOBIQ&#xAE; No-Code platform for development of mobile applications, today announced the signing, on June 18, 2025, of a memorandum of understanding (MOU) with Evvo Labs Pte. Ltd, an ITMS technology company in Singapore, to develop a large language model (LLM) tailored for software engineering and application development.
The LLM will be integrated into Orangekloud's eMOBIQ platform and other solutions, offering intelligent suggestions, code generation, testing automation, and system integration support. It will also enhance ERP implementation and software development cycles through automated documentation, code audits, and AI-guided system configuration.
This strategic development builds on the Company's experience helping organizations implement complex ERP systems and its success with its eMOBIQ no-code App development platform, which enables businesses and individuals to create powerful web and mobile applications with virtually no coding.
The project is expected to enter pilot testing in the first quarter of 2026.

ORKT

Orangekloud Signs MOU With Evvo Labs To Develop Large Language Model Tailored For Software Engineering And Application Development

NLSP

NLS Pharmaceutics shares are trading higher after the company announced it completed its second and final equity financing round consisting of preferred shares and warrants worth $3 million in total.

CLOV

Clover Health Investments Set To Join Broad-Market Russell 3000 Index

Chief Financial Officer
Bret D. McLeod, 42, will join the Company in July 2025 as Executive Vice President - Finance and assume the Chief Financial Officer role on August 7, 2025. Mr. McLeod currently serves as Executive Vice President and CFO of Great Wolf Resorts. He is a seasoned senior financial executive with extensive experience in corporate strategy, capital markets, operations and investor relations at both public and private companies. Prior to Great Wolf, he served as CFO for Citycon, a publicly listed owner of Nordic shopping centers. Before that, he spent nearly 15 years at Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>), serving in positions of increasing responsibility, most recently as Senior Vice President, Treasurer, Head of Strategy &amp; Investor Relations. Mr. McLeod has a BSBA in Finance and Management from Georgetown University and an MBA from Northwestern University's Kellogg School of Management.

Equity Residential Announces Bret D. McLeod Will Join The Company In July 2025 As Executive Vice President - Finance And Assume The Chief Financial Officer Role On August 7, 2025

JP Morgan analyst Kenneth Worthington initiates coverage on Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) with a Underweight rating and announces Price Target of $80.

CRCL

JP Morgan Initiates Coverage On Circle Internet Group with Underweight Rating, Announces Price Target of $80

ABBV

AbbVie To Acquire Capstan Therapeutics For Up To  $2.1B In Cash At Closing

GAME

GameSquare Holdings shares are trading higher. The company announced it entered into an at-the-market sales agreement to sell $9.25 million worth of shares.

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain
PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy
THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=bMRz80IWR0mWmhxk9Hbuocv84j8INYNJFjkuvQ_YyFp88stsYQv_6mEltt7xjhzd-n3AO0ZQdk503KHsNL2gYTssZhcHpSb-yAkL1BeJMlo=">Autonomix Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical trial ("PoC 2") evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain.

AMIX

Autonomix Medical Announces The First Patient Has Been Enrolled And Treated In The Follow-On Phase To Its Proof-Of-Concept Human Clinical Trial Evaluating The Safety And Effectiveness Of Delivering Transvascular Energy To Ablate Relevant Problematic Nerves And Mitigate Cancer Pain

System1 shares are trading higher. The company announced a $250 million common stock offering.

GIBO Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>), a leading innovator in intelligent content infrastructure, today announced the successful testing of its AI-driven engine, <a href="https://globalibo.com/gibo-click/">GIBO Click</a>, on <a href="https://play.google.com/store/apps/details?id=com.udrama.ruiqilin&amp;hl=en">uDrama</a>, a rising star in the global short drama landscape.
Since launching in May 2024, <a href="https://play.google.com/store/apps/details?id=com.udrama.ruiqilin&amp;hl=en">uDrama</a> has rapidly gained traction in North America, Japan, Korea, and Southeast Asia, specializing in 1–2-minute short dramas that appeal to modern digital viewing habits. The platform supports a versatile monetization model, combining in-app purchases, advertisements, and subscriptions to serve a broad spectrum of global consumers.
As of June 2025, uDrama has grown to more than 1.1 million users, with 120,000 daily active users (DAU) and a rich content library of over 1,000 titles.
GIBO Click: Integrating Smart Commerce with Audience Intelligence
The trial deployment of GIBO Click brings powerful capabilities to uDrama's backend ecosystem, including:
<ul>
<li>Seamless Multicurrency Settlement: Handles diverse regional payments with adaptive logic for international markets</li>
<li>AI-Driven Viewership Analysis: Provides deep insights into user preferences, completion rates, and content interaction patterns</li>
<li>Modular Monetization Architecture: Supports flexible models such as pay-per-episode, bundled access, and user-specific pricing tiers</li>
</ul>
Following successful validations with Honey Reels and YouShort, this latest test with uDrama further affirms GIBO Click's utility as a modular enabler for the fast-growing short drama industry.

GIBO

GIBO Holdings' AI-Powered GIBO Click Successfully Tested On Growing Short Drama Platform, uDrama

The U.S. Food and Drug Administration (FDA) announced on Friday that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">CAR T cell immunotherapies</a>.&nbsp;
These products are gene therapies currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma.
&#8220;The FDA has taken the bold step to remove the Risk Evaluation and Mitigation Strategy requirement from giving CAR T therapies. REMS is a useful safety system, but reevaluation over time helps inform whether a REMS is still needed to ensure that the benefits of a product outweigh its risks,&#8221;&nbsp;said FDA Vinay Prasad, Chief Medical and Scientific Officer and Director, Center for Biologics Evaluation and Research.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46144447/fda-eases-rules-for-bristol-myers-cell-therapies-for-blood-cancers" rel="noreferrer noopener">FDA Eases Rules For Bristol Myers&#8217; Cell Therapies For Blood Cancers</a>
&#8220;Eliminating the REMS that is no longer needed also expedites the delivery of potentially curative treatments to patients and reduces the burden on providers,&#8221; he added.
A REMS is a safety <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor" rel="noreferrer noopener">program</a> that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.
The FDA determined that the approved REMS for the f<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se" rel="noreferrer noopener">ollowing products should be eliminated</a> because a REMS is no longer necessary to ensure that the benefits of the autologous CAR T cell immunotherapies outweigh their risks.&nbsp;
The products affected by this change include Bristol Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel), Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Carvykti (ciltacabtagene autoleucel), Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Kymriah (tisagenlecleucel), and Gilead Science Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).
The elimination of REMS for the above products removes the requirements that hospitals and their associated clinics that dispense products must be specially certified and have on-site, immediate access to tocilizumab.
&#8220;Continuous monitoring and assessment of the safety of all biological products, including the CAR T cell immunotherapies, is an FDA priority and we remain committed to informing the public when we learn new information about these products,&#8221; the FDA said in a press release.
As per a <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor" rel="noreferrer noopener">safety</a> statement on Thursday, the regulator also reduced its requirement that patients remain near the facility where they received treatment to two weeks. The agency also removed its advice to patients to avoid driving for two weeks following product administration.
Commenting on the development and accessibility of CAR T-cell therapies, William Blair said, &#8220;Overall, we view the removal of the REMS program for CAR-T cell therapies as a positive development for the space, as it supports the notion that the FDA is working to minimize red tape and increase access to potentially curative treatments for patients. We also believe the removal of the REMS requirements could increase access and use of these therapies in the community settings.&#8221;
Analyst Sami Corwin said the update also suggests there will likely be no REMS requirements for CD19 and BCMA autologous CAR-T cell therapies approved in the future, such as Arcellx, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) anito-cel.
Moreover, Corwin highlighted the positive implications for companies developing CAR T-cell therapies for autoimmune diseases, such as Autolus Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>), Bristol-Myers, and Cabaletta Bio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>), &#8220;given that the safety profile is more tolerable than in oncology.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46163176/microsoft-stock-could-soar-44-on-ai-boom-analyst-says-but-theres-a-catch" target="_blank" rel="noreferrer noopener">Microsoft Stock Could Soar 44% On AI Boom, Analyst Says — But There&#8217;s A Catch</a></li>
</ul>
Photo by Tada Images via Shutterstock

Large Cap

Health Care

ACLX

AUTL

CABA

GILD

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers

Press Releases

BBAI LAWSUIT ALERT: Levi & Korsinsky Notifies BigBear.ai Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

BigBear.ai Joins Forces with Analogic to Transform Airport Threat Detection

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BigBear.ai

Leaders in The News: BBAI, SYTA, FCEL, LTRY 

AI for Gaming and Military Applications, Clean Energy, and Digital Transformation of $340 Billion Global Lotto Market

BBAI Deadline Today: Rosen Law Firm Urges BigBear.ai Holdings, Inc. (NYSE: BBAI) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Legal

BigBear.ai Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 10, 2025 to Discuss Your Rights – BBAI

BigBear.ai, Easy Lease, and Vigilix Announce Strategic Partnership in the UAE

Kuehn Law Encourages Investors of BigBear.ai Holdings, Inc. to Contact Law Firm

BIGBEAR ALERT: Bragar Eagel & Squire, P.C. is Investigating BigBear.ai Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

BigBear.ai Deploys Enhanced Passenger Processing Biometric Technology at Major Ports of Entry, including U.S. and International Airports

BBAI

FCEL

LTRY

SYTA

Accenture plc Class A Ordinary Shares (Ireland)

Accenture

ASGN

Alpha Technology Group Limited - Class A Ordinary Shares

Alpha Technology Group

CI&T

Castellum

Cognizant Technology Solutions Corporation - Class A Common Stock

Cognizant Tech Solns

Endava plc American Depositary Shares (each representing one Class A Ordinary Share)

Comments

BigBear.ai Hldgs

ニュース

最新ニュース BigBear.ai Hldgs (NYSE:BBAI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル